Clinical trials for cell and gene therapies (CGT) present unique challenges as they require special resources and training.
![](https://icon.widen.net/content/10a51980-50ca-486c-8ed5-4aa5a6ad126e/web/Lachs_Martin_5.png?crop=yes&w=240&h=240&itok=kSEYfMwO)
Martin Lachs
![](https://icon.widen.net/content/dd2e9a57-438b-4c40-bfc9-040885a4c2b8/web/Saulin_Oliver_5-.png?crop=yes&w=240&h=240&itok=OV1uhGG8)
Olivier Saulin
![](https://icon.widen.net/content/025c8531-c348-4613-b347-cbc53336a459/web/Joeckel_Tamie_10.png?crop=yes&w=240&h=240&itok=-w_4yn7i)
Tamie Joeckel
In a recent podcast interview, our experts Brandon Fletcher (Cell and Gene Therapy Principal), Tamie Joeckel (Cell and Gene Therapy Business Lead), Martin Lachs (Vice President, Project Management) and Olivier Saulin (Cell and Gene Therapy Principal) discuss the intricacies of CGT development, the solutions that will enable CGT development on a global basis, and the future of CGT clinical trials.
Q: What are the unique challenges posed by manufacturing and developing CGTs?
ML: There’s a whole raft of challenges in the development space – from logistics to manufacturing to patient safety to the limitation on facilities that can actually administer these drugs. One challenge is that no two studies are necessarily alike. For example, you can’t assume that autologous studies are the same as allogeneic studies, or that the needs within them are the same. There are lots of commonalities, of course. You’re still talking about a living therapy. But when it comes to processes, such as apheresis, there are different nuances that have to be taken into account.
Q: What patient recruitment challenges have you faced, in particular for oncology and the rare diseases?
ML: When we started doing these trials about five years ago, it was very easy to find willing patients because the results were very hopeful, and they continue to be in terms of response rates and durability. But now, the space has become quite congested. At the same time, there are alternative and cheaper treatments that are more accessible to a broader number of physicians and hospital institutions. This competition, not just from the CGT space, but also from other therapies, such as immunotherapies and so on, is putting pressure on enrolment capabilities and capacities.
TJ: The implications of rare disease patient recruitment are obvious: we’re looking at an extremely small patient population. Not only rare, but in many cases ultra-rare. It’s really important to understand where these patients are located. For example, when we were starting a study on severe combined immune-deficiency, we worked very closely with patient advocacy groups. These groups are already providing support services to these patients and know where these families are and they can help us build awareness within the community about the availability of the trial.
Q: How is trial design evolving to meet the needs of the CGT space, and what are the biggest innovations you are seeing in this area?
OS: One of the most innovative trials we recently worked on involved evaluating patients based on the presence of cancer-specific antigens in solid tumors, regardless of the tumor type. The study tested the effect of drugs in a variety of cancer histologies, which allowed us to test a lot of different tumor types. This, in turn, helped us to quickly determine which specific tumor type to concentrate on.
ML: In terms of oncology development and beyond, we’re seeing that trials are becoming more registration-focused at an earlier phase. There’s a move towards more adaptive designs, such as basket type trials, umbrella trials and platform trials. We’re trying to combine as many treatment groups within the framework of a single trial as possible.
Q: What would you consider to be the hot topics in CGT development, and how can CROs, in particular, be involved in addressing them?
ML: Cost is probably the largest tangible challenge, if you look into the commercialisation of what are otherwise extraordinarily exciting technologies. Not just the cost of doing trials, which is not trivial, but also the cost of the product once you get close to commercialisation. When you factor in the additional costs of hospitals administering treatment and general care for the patient, they have an even higher price. A lot of development is targeted towards managing that cost downwards, whether it’s through allogeneic therapies, which arguably should be a lot cheaper, or in other ways.
Realistically, we can work to support companies as we do because we have our own pricing, market access, and commercialisation groups who are experts at looking at things such as net present value and doing full evaluations on potential.
Q: Looking to the future, what do you predict as the key challenges and opportunities for the CGT sector within the next 5 to 10 years?
BF: A strong focus will be on streamlining logistics and reducing cost to truly support the opportunity of access. In oncology, the field still awaits a clear demonstration of clinical efficacy of CGTs in solid tumors. This challenge is becoming a defining issue in cellular immunology as the new decade begins. Solid tumors make up almost 80 percent of all cancers, and the key challenge is creating and managing therapies that can manipulate and/or withstand the inhospitable environments of these tumors, known as the tumor microenvironment. In the future we’ll see a focus on bringing these therapies to solid tumors in a meaningful and effective way.
Our knowledge of disease, the genome and tissues still far outweighs our ability to respond from a medical technology perspective. In the CGT world, the emergence and elevation of gene editing technologies is key. As gene therapies and genetically modified cell therapies leverage these emerging gene editing technologies, coupled with ever more optimal material resources, the future of CGTs is more than just promising – it’s tangible.
Learn more about our offerings for CGT trials, or contact us to speak to one of our experts.
Cell and gene therapies insights
ICON's Cell and Gene Therapies team contributes regularly to industry publications and media coverage of cell and gene therapy clinical trials. Stay up to date with the latest trends in this therapeutic area through ICON's insights.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel